Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry
September 05, 2018 11:15 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE - - Immune Therapeutics, Inc. (OTCQB: IMUN), a late stage biopharmaceutical company focused on the development of therapies for the...
Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board
August 23, 2018 09:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune Therapeutics", "IMUN" or the "Company"), a late stage clinical biopharmaceutical...
Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors
August 07, 2018 08:00 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage T-Cell Activation...
Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies
July 25, 2018 08:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Research on Lodonal for HIV related GI complications featured in Plus Magazine
July 19, 2018 08:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., July 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States
June 05, 2018 12:14 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company...
Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States
June 05, 2018 08:00 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company...
Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic
April 26, 2018 08:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease
March 26, 2018 09:35 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused...
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
February 20, 2018 08:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused...